Expertise in
11
conditions

Giancarlo Castaman

Florence, IT 
Expertise in
11
conditions
Florence, IT 

Overview

Giancarlo Castaman practices practicing medicine in Florence, Italy.

Mr. Castaman is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Blood Clots, Hemophilia B, Hemophilia A, and Von Willebrand Disease (VWD).

He is actively involved in clinical research, co-authoring 246 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Florence, Italy
Other Locations
Careggi, Italy
Vicenza, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Enrollment Status: Completed
Publish Date: March 27, 2026
Intervention Type: Genetic, Biological
Study Drug: AMT-061 Adeno-Associated Virus Padua Variant FIX Vaccine
Study Phase: Phase 3
A Phase 3b, Prospective, Open-Label, Uncontrolled, Multicenter Study on Long-Term Safety and Efficacy of rVWF in Pediatric and Adult Subjects With Severe Von Willebrand Disease (VWD)
A Phase 3b, Prospective, Open-Label, Uncontrolled, Multicenter Study on Long-Term Safety and Efficacy of rVWF in Pediatric and Adult Subjects With Severe Von Willebrand Disease (VWD)
Enrollment Status: Completed
Publish Date: September 03, 2025
Intervention Type: Biological
Study Drugs: Von Willebrand Factor, Factor VIII
Study Phase: Phase 3
Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)
Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)
Enrollment Status: Completed
Publish Date: July 28, 2025
Intervention Type: Biological
Study Drugs: PEG-Factor VIII, Eloctate ITI
Study Phase: Phase 3
An Open-Label, Multinational, Phase 1/2 Study of the Safety and Dose Escalation of SHP648, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing FIX Padua in Hemophilia B Subjects
An Open-Label, Multinational, Phase 1/2 Study of the Safety and Dose Escalation of SHP648, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing FIX Padua in Hemophilia B Subjects
Enrollment Status: Terminated
Publish Date: May 19, 2022
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
A Phase 3, Multicenter, Open-label Study of the Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (BAX 802) in Subjects With Congenital Hemophilia A With Factor VIII Inhibitors Undergoing Surgical or Other Invasive Procedures
A Phase 3, Multicenter, Open-label Study of the Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (BAX 802) in Subjects With Congenital Hemophilia A With Factor VIII Inhibitors Undergoing Surgical or Other Invasive Procedures
Enrollment Status: Terminated
Publish Date: October 20, 2021
Intervention Type: Biological
Study Phase: Phase 3
View 4 Less Clinical Trials

245 Total Publications

Von Willebrand disease: classification and epidemiology.
Von Willebrand disease: classification and epidemiology.
Journal: Haematologica
Published: December 11, 2025

Frequently Asked Questions about Giancarlo Castaman

Is Giancarlo Castaman a top-rated expert for Blood Clots?

MediFind is an objective health platform that identifies experts based on real-world data. Giancarlo Castaman is classified as an Elite expert for Blood Clots, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Giancarlo Castaman participate in research or clinical trials?

Yes. Giancarlo Castaman has published 245 articles and abstracts on conditions like Blood Clots. You can view a list of Giancarlo Castaman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Castaman's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile